The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Open accessAbstract
CONTEXT: Activation of peroxisome proliferator-activated receptor-gamma by thiazolidinediones (TZDs) results in lower bone mass in mice. OBJECTIVE: The objective of the study was to determine whether TZD use is associated with changes in bone mineral density (BMD) in older adults with type 2 diabetes. DESIGN: We analyzed 4-yr follow-up data from the Health, Aging, and Body Composition observational study. SETTING: The study was conducted in a general community. PATIENTS: White and black, physically able men and women, aged 70-79 yr at baseline with diabetes defined by self-report, use of hypoglycemic medication, elevated fasting glucose (>/=126 mg/dl), or elevated 2-h glucose tolerance test (>/=200 mg/dl) participated in the study. MAIN OUTCOME MEASURES: Whole-body, lumbar spine (derived from whole body), and hip BMD were measured by dual-energy x-ray absorptiometry at 2-yr intervals. RESULTS: Of 666 diabetic participants, 69 reported TZD use at an annual visit, including troglitazone (n = 22), pioglitazone (n = 30), and/or rosiglitazone (n = 31). Those with TZD use had higher baseline hemoglobin A(1c) and less weight loss over 4 yr but similar baseline BMD and weight than others with diabetes. In repeated-measures models adjusted for potential confounders associated with TZD use and BMD, each year of TZD use was associated with greater bone loss at the whole body [additional loss of -0.61% per year; 95% confidence interval (CI) -1.02, -0.21% per year], lumbar spine (-1.23% per year; 95% CI -2.06, -0.40% per year), and trochanter (-0.65% per year; 95% CI -1.18, -0.12% per year) in women, but not men, with diabetes. CONCLUSION: These observational results suggest that TZDs may cause bone loss in older women. These results need to be tested in a randomized trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Generalized, Linear, and Mixed Models
McCulloch, C. E., & Searle, S. R. (2000) · Wiley Series in Probability and Statistics · doi:10.1002/0471722073 · Cited by 2,994
Older Women with Diabetes Have an Increased Risk of Fracture: A Prospective Study
Schwartz, A. V. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.32 · Cited by 789
Self-citationBone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study.
de Liefde, I. I., van der Klift, M., de Laet, C. E. D. H., van Daele, P. L. A., Hofman, A., & Pols, H. A. P. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1909-1 · Cited by 555
Azziz, R., Ehrmann, D., Legro, R. S., Whitcomb, R. W., Hanley, R., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7375 · Cited by 517
Drug data coding and analysis in epidemiologic studies
Pahor, M., Chrischilles, E. A., Guralnik, J. M., Brown, S. L., Wallace, R. B., & Carbonin, P. (1994) · European Journal of Epidemiology · doi:10.1007/bf01719664 · Cited by 490
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka-Czernik, B. (2004) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 454
Self-citationStrotmeyer, E. S., Cauley, J. A., Schwartz, A. V., Nevitt, M. C., Resnick, H. E., Bauer, D. C., Tylavsky, F. A., de Rekeneire, N., Harris, T. B., & Newman, A. B. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1612 · Cited by 377
Self-citationAzziz, R. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1626 · Cited by 376
Strotmeyer, E. S., Cauley, J. A., Schwartz, A. V., Nevitt, M. C., Resnick, H. E., Zmuda, J. M., Bauer, D. C., Tylavsky, F. A., de Rekeneire, N., Harris, T. B., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040311 · Cited by 218
Self-citation
Cited by
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“[Use of TZDs for treating T2DM is associated with greater bone loss in women (Schwartz et al., 2006).]”
MethodAge-related changes in total and regional fat distribution
Kuk, J. L., Saunders, T. J., Davidson, L. E., & Ross, R. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.06.001 · Cited by 778
“It is reported that thiazolidinediones may increase adipogenesis and decrease osteoblast formation in the bone marrow of mice (Rzonca et al., 2004) and diabetic women, but not men (Schwartz et al., 2006).”
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
“Theconsensusalgorithm forthemanagement oftype 2diabetes mellitus was developed on behalf of the American Diabetes Association and the European Association for the Study of Diabetes approximately 1 year ago [ 1 , 2]. This evidence-based algorithm was developed to help guide healthcare providers to choose the most appro…”
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
“The only suggestion that this could occur had come from an epidemiological study of 69 diabetic women aged 70 –79 years who manifested increased bone mineral loss with thiazolidinedione treatment (9).”
BackgroundWnt and PPARγ signaling in osteoblastogenesis and adipogenesis
Takada, I., Kouzmenko, A. P., & Kato, S. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.137 · Cited by 504
Osteoporosis in Patients With Diabetes Mellitus
Hofbauer, L. C., Brueck, C. C., Singh, S. K., & Dobnig, H. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070510 · Cited by 503
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Side effects that have limited TZD use include weight gain, increased bone fracture risk in postmenopausal women and elderly men, and elevated risk for chronic edema or heart failure (113-116).”
BackgroundTakada, I., Mihara, M., Suzawa, M., Ohtake, F., Kobayashi, S., Igarashi, M., Youn, M.-Y., Takeyama, K.-I., Nakamura, T., Mezaki, Y., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1647 · Cited by 424
RetractedFracture Risk in Type 2 Diabetes: Update of a Population-Based Study
Melton, L. J., Leibson, C. L., Achenbach, S. J., Therneau, T. M., & Khosla, S. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080323 · Cited by 416
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2646 · Cited by 401
Kang, S., Bennett, C. N., Gerin, I., Rapp, L. A., Hankenson, K. D., & MacDougald, O. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700030200 · Cited by 401
FRAX underestimates fracture risk in patients with diabetes
Giangregorio, L. M., Leslie, W. D., Lix, L. M., Johansson, H., Oden, A., McCloskey, E., & Kanis, J. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.556 · Cited by 387
Bone, sweet bone—osteoporotic fractures in diabetes mellitus
Hamann, C., Kirschner, S., Günther, K.-P., & Hofbauer, L. C. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.233 · Cited by 380
Use of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
Yamamoto, M., Yamaguchi, T., Yamauchi, M., Kaji, H., & Sugimoto, T. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081207 · Cited by 327
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2008) · Diabetes Care · doi:10.2337/dc08-9016 · Cited by 326
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
David, V., Martin, A., Lafage-Proust, M.-H., Malaval, L., Peyroche, S., Jones, D. B., Vico, L., & Guignandon, A. (2007) · Endocrinology · doi:10.1210/en.2006-1704 · Cited by 321
The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone
Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., & Lecka-Czernik, B. (2007) · Endocrinology · doi:10.1210/en.2006-1587 · Cited by 302
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
Giacomini, K. M., Krauss, R. M., Roden, D. M., Eichelbaum, M., Hayden, M. R., & Nakamura, Y. (2007) · Nature · doi:10.1038/446975a · Cited by 276
Almeida, M., Ambrogini, E., Han, L., Manolagas, S. C., & Jilka, R. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.023572 · Cited by 275
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
Yamamoto, M., Yamaguchi, T., Yamauchi, M., Yano, S., & Sugimoto, T. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1270 · Cited by 264
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
“Furthermore, given the recent observations of reduced bone density and increased fracture rates in diabetic subjects treated with thiazolidinediones,((51)) the combined use of GLP‐1 receptor agonists and thiazolidinedionesmay have clinical significance.”
BackgroundHow safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Sadie-Van Gijsen, H., Hough, F. S., & Ferris, W. F. (2013) · Bone · doi:10.1016/j.bone.2013.06.016 · Cited by 48
Metadata
- Authors
- Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., Park, S. W., Lane, N. E., Harris, T. B., & Cummings, S. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-09
- Volume
- 91
- Issue
- 9
- Pages
- 3349-3354
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2116822087
- Cited by
- 500
- References
- 26
- FWCI
- 54.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.